대한핵의학회지 (1967년~2009년)
Nucl Med Mol Imaging 2008;42(4)307~313
원저 : 흑색종에서의 I-131표지 혈관내피세포성장인자 수용체2 항체를 이용한 방사면역치료 평가
(Evaluation of the Radioimmunotherapy Using I-131 Labeled Vascular Endothelial Growth Factor Receptor2 Antibody in Melanoma Xenograft Murine Model)
Author 김은미, 정환정, 박은혜, 정수진, 이창문, 장규윤1, 김동욱, 임석태, 손명희,
Eun-Mi Kim, M.S., Hwan-Jeong Jeong, M.D., Eun-Hye Park, M.S., Su-Jin Cheong, M.S., Chang-Moon Lee, Ph.D., Kyu-yun Jang, M.D.1, Dong Wook Kim, Ph.D., Seok Tae Lim, M.D., and Myung Hee Sohn, M.D.
Affiliation 전북대학교 의학전문대학원 핵의학교실, 임상연구소, 의과학연구소
Departments of Nuclear Medicine and 1Pathology, Research Institute of Clinical Medicine, Institute for Medical Sciences, Chonbuk National University Medical School and Hospital, Jeonju, Korea
Abstract

Purpose: Vascular endothelial growth factor (VEGF) and its receptor, fetal liver kinase 1 (Flk-1), play an important role in vascular permeability and tumor angiogenesis. The aim of this study is to evaluate the therapeutic efficacy of 131I labeled anti-Flk-1 monoclonal antibody (DC101) on the growth of melanoma tumor, which is known to be very aggressive in vivo. Materials and Methods: Balb/c nude mice were injected subcutaneously with melanoma cells in the right flank. Tumors were allowed to grow up to 200-250 mm3 in volume. Gamma camera imaging and biodistribution studies were performed to identify an uptake of 131I-DC101 in various organs. Mice with tumor were randomly divided into five groups (10 mice per group) and injected intravenously; control PBS (group 1), 131I-DC101 50 μg/mouse (group 2), non-labeled DC101 50 μg/mouse (group 3), 131I-DC101 30 μg/mouse (group 4) and 15 μg/mouse (group 5) every 3 or 4 days for 20 days. Tumor volume was measured with caliper twice a week. Results: In gamma camera images, the uptake of 131I-DC101 into tumor and thyroid was increased with time. Biodistribution results showed that the radioactivity of blood and other major organ was gradually decreased with time whereas tumor uptake was increased up to 48 hr and then decreased. After 4th injection of 131I-DC101, tumor volume of group 2 and 4 was significantly smaller than that group 1. After 5th injection, the tumor volume of group 5 also significantly reduced. Conclusion: These results indicated that delivery of 131I to tumor using Flk-1 antibody, DC101, effectively blocks tumor growth in aggressive melanoma xenograft model.

Keyword adioimmunotherapy, vascular endothelial growth factor receptor 2, melanoma
Full text Article 4204307313.pdf 4204307313.pdf
(03121)서울시 종로구 지봉로 29 금호팔레스빌딩 1705호
TEL : 02-745-2040 FAX : 02-745-3833 E-mail : ksnm@ksnm.or.kr
Copyright 2012 by The Korean Society of Nuclear Medicine(KSNM)